Pork collagen

• Monteloeder's Nutroxsun, a rosemary and grapefruit extract formulation, demonstrated significant reduction in UV-induced skin redness in a randomized, placebo-controlled crossover trial with 20 participants. • The study showed dose-dependent effects, with 250mg reducing redness by 41% compared to 62.7% in placebo group 24 hours after UV exposure. • Results published in International Journal of Molecular Sciences indicate the formulation helps modulate matrix metalloproteinases and reduces oxidative stress markers associated with collagen degradation. • The clinical findings support Nutroxsun's potential as a beauty-from-within supplement for photoprotection and anti-aging applications in the nutraceutical market.

• Taiwan's ACRO Biomedical has received regulatory approval from Taiwan's Ministry of Health and Welfare for its ABCcolla® Collagen Ophthalmic Matrix, offering a breakthrough solution for corneal transplantation. • The product utilizes proprietary supercritical carbon dioxide decellularization technology to process porcine corneas into biocompatible alternatives to human donor tissue, potentially addressing the severe global shortage where only 100,000 of 20 million patients receive transplants annually. • With patents in 15 countries and proven efficacy for corneal damage from trauma, infections, and melting, the technology positions ACRO Biomedical to capitalize on a market expected to grow from $500 million in 2024 to $1 billion by 2033.

• SolasCure has enrolled the first patient in CLEANVLU2, a randomized controlled Phase II trial testing a higher concentration of Tarumase enzyme in their Aurase Wound Gel for venous leg ulcers. • Aurase Wound Gel contains Tarumase, a recombinant enzyme derived from medical maggots that selectively targets fibrin, collagen, and elastin to promote wound healing through debridement. • The trial follows a successful Phase IIa study that established proof-of-concept, safety profile, and pain-free application, addressing a significant healthcare challenge affecting approximately 100 million people globally.

• Stuart Therapeutics has completed its Phase 3 clinical trial of ST-100 (vezocolmitide) for treating Dry Eye Disease, marking a significant milestone. • The Phase 3 trial was a randomized, double-blind, vehicle-controlled study evaluating the efficacy, safety, and tolerability of ST-100. • ST-100, a collagen mimetic peptide, aims to repair disease-damaged collagen in the eye, potentially offering rapid relief and improved tear function. • Topline data from the Phase 3 trial is expected in February 2025, with Stuart Therapeutics planning to share the results in Q1 2025.

• Researchers have identified dextromethorphan, a common cough medicine ingredient, as a potential treatment for lung fibrosis by inhibiting collagen production. • The study utilized high-throughput microscopy and proteomics to identify dextromethorphan's mechanism of action in reducing scar tissue formation in the lungs. • Experiments in mouse models and human lung tissue cultures demonstrated that dextromethorphan effectively impedes collagen, reducing lung fibrosis. • Phase II clinical trials are being planned to investigate the efficacy of dextromethorphan in human patients with lung fibrosis, offering a potential new therapeutic avenue.